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A classification system has been proposed to standardize the
definition of acute kidney injury in adults. These criteria of
risk, injury, failure, loss, and end-stage renal disease were
given the acronym of RIFLE. We have modified the criteria
based on 150 critically ill pediatric RIFLE (pRIFLE) patients to
assess acute kidney injury incidence and course along with
renal and/or non-renal comorbidities. Of these children,
11 required dialysis and 24 died. Patients without acute
kidney injury in the first week of intensive care admission
were less likely to subsequently develop renal Injury or
Failure; however, 82% of acute kidney injury occurred in this
initial week. Within this group of 123 children, 60 reached
pRIFLEmax for Risk, 32 reached Injury, and 31 reached
Failure. Acute kidney injury during admission was an
independent predictor of intensive care; hospital length of
stay and an increased risk of death independent of the
Pediatric Risk of Mortality (PRISM II) score (odds ratio 3.0).
Our results show that a majority of critically ill children
develop acute kidney injury by pRIFLE criteria and do so early
in the course of intensive care. Acute kidney injury is
associated with mortality and may lead to increased hospital
costs. We suggest that the pRIFLE criteria serves to
characterize the pattern of acute kidney injury in critically ill
children.
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More than 30 acute kidney injury (AKI) definitions exist in the
published literature.1 Lack of a standardized definition that can
be applied across patient populations (1) impedes rational
comparison of studies that assess preventive and therapeutic
AKI strategies, (2) limits generalization of data generated from
single center studies, and (3) prevents patient stratification
based on AKI severity. Recent pediatric AKI epidemiological
data for critically ill children demonstrates a shift from primary
renal disease to injury secondary to other systemic illnesses
and/or their treatment.2,3 Widespread availability of aggressive
treatment options, such as bone marrow and solid organ
transplantation for children, has led to increased exposure to
nephrotoxic medications and more critically ill children
receiving intensive care. The incidence of pediatric AKI in this
at-risk population still remains unknown.
The reported mortality from AKI is still as high as 60% in
critically ill children.4 Most of the reported clinical studies of
pediatric AKI focus on patients requiring renal replacement
therapy (RRT), who have clearly experienced severe renal
injury.5–10 However, recent studies demonstrate that even a
modest rise in serum creatinine (SCr) is a risk factor for
mortality in adult and pediatric patients.11,12 Thus, SCr may
be an insensitive marker of early AKI and reliance on SCr
hampers early AKI recognition. Extensive study has focused
upon investigation of urinary biomarkers that detect AKI
earlier than a rise in SCr.13–15
A new classification system, termed the ‘RIFLE criteria,’ has
been proposed for use in critically ill adult patients by the Acute
Dialysis Quality Initiative group.1 RIFLE (acronym for Risk for
renal dysfunction, Injury to the kidney, Failure of kidney
function, Loss of kidney function, and End-stage renal disease
(ESRD)) aims to standardize the definition of AKI by stratifying
patients based on changes in SCr levels from baseline and/or an
abrupt decrease in urine output (UOP). We aimed to study a
modified pediatric version of the RIFLE criteria (pRIFLE) to (1)
describe the epidemiology and clinical course of AKI in
critically ill children and (2) explore the potential relationships
between AKI and renal and non-renal morbidities.
RESULTS
Group characteristics
We prospectively enrolled 150 critically ill patients (55.3%
males) over a 12-month period. Mean age was 6.476.4 years
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2007 International Society of Nephrology
Received 21 December 2006; revised 21 January 2007; accepted 6
February 2007; published online 28 March 2007
Correspondence: SL Goldstein, Renal Section, Department of Pediatrics,
Baylor College of Medicine, Texas Children’s Hospital, 6621, Fannin Street,
MC3-2482, Houston, TX 77030, USA. E-mail: stuartg@bcm.tmc.edu
1028 Kidney International (2007) 71, 1028–1035
(median¼ 4 years, range¼ 1 month–21 years). Mean Pedia-
tric Risk of Mortality (PRISM II) score at pediatric intensive
care unit (PICU) admission was 14.978.4 (median¼ 15).
Seventy-one percent of patients had preexisting chronic
conditions. All patients received invasive mechanical ventila-
tion (mean duration¼ 14.5717.6days; median¼ 9,
range¼ 1–100 days). Fifty-three percent (80/150) of patients
received vasoactive medications (17.5% received one, 18.1%
two and 17.4% three or more). Mean PICU and hospital
length of stay (LOS) were 16.6722.4 and 33.7738.1 days,
respectively (median (range)¼ 10 (2–192), and 21 (2–24),
respectively). Twenty-eight days and overall hospital mortal-
ity were 14% and 16%, respectively. Eleven patients (7.3%)
received acute RRT.
Mean baseline estimated creatinine clearance (eCCl) for
the entire cohort was 154793 ml/min/1.73 m2 (med-
ian¼ 124 ml/min/1.73 m2, range¼ 41–924 ml/min/1.73 m2).
Forty-one patients (27%) did not have baseline SCr values
and were assigned baseline eCCl of 100 ml/min/1.73 m2.
Twenty-six patients had known pre-admission chronic
neuromuscular disorders (NMd) associated with prolonged
immobilization, resulting in severely decreased muscle mass
(e.g., muscular dystrophy, cerebral palsy, quadriplegia, etc.).
Mean eCCl for the NMd subset was 2327173 ml/min/
1.73 m2 (median¼ 213 ml/min/1.73 m2). Mean baseline eCCl
for the non-NMd cohort (n¼ 124) was 138755 ml/min/
1.73 m2 (median¼ 118 ml/min/1.73 m2).
Incidence and clinical course of AKI
Twenty-seven patients did not develop AKI and served as
controls, 123 patients (82%) developed AKI by pRIFLE:
48.8% of these reached pRIFLEmax R (n¼ 60), 26.0%
reached I (n¼ 32), and 25.2% reached F (n¼ 31). Table 1
displays the comparison of characteristics between
patients with and without AKI. There were no statistically
significant differences in any of the baseline demographic
characteristics between patients with vs without AKI.
PICU admission diagnoses, comorbidities, vasopressor re-
quirements, peak mean airway pressures, and days of
ventilation also did not differ between patients with vs
without AKI.
Higher pRIFLEmax strata were associated with higher
PRISM II scores. Mean PRISM II scores for controls, R, I, and
F were 12.477.2, 13.077.7, 15.978.0, and 19.679.3,
respectively (Po0.001 by one-way analysis of variance).
Mean time to onset of the first pRIFLE stratum was
3.373.1 days after PICU admission (median¼ 2,
range¼ 1–14 days). Eighty-two percent (101/123) of patients
developed AKI within the first 7 days of PICU admission
(Figure 1). Patients who did not develop AKI within the first
7 days of PICU admission were very unlikely to subsequently
develop severe AKI (negative predictive value (NPV) of
reaching pRIFLEmax I or F¼ 95.1%, Po0.001; NPV of
reaching pRIFLEmax F¼ 97.7%, Po0.001). Patients who
remained free of AKI in the first 7 days did not receive RRT
(NPV 100%, P¼ 0.03).
Twenty-six percent of patients with initial pRIFLE R or I
progressed to a higher pRIFLE stratum. Patients with initial
pRIFLE I were more likely to progress to pRIFLEmax F than
those with initial pRIFLE R (12/31 (39%) vs 3/76 (4%),
Po0.0001).
Figure 2 summarizes AKI distribution and outcomes
comparing patients with and without chronic NMd. We
chose to examine the NMd group separately because it is
unknown whether change in SCr/eCCl is as reliable a marker
of change in renal function in this unique group, owing to
severely reduced muscle mass. The AKI prevalence and AKI
Table 1 | Comparison of characteristics of patients with versus
without AKI
Control n=27
(18%)
AKI by RIFLE
n=123 (82%)
Continuous variables
Mean7s.d., median
Age (years) 6.076.6 (1.25) 6.576.3 (4.0)
Weight (kg) 21.7718.1 (12.0) 26.1723.6 (16.0)
Height (cm) 103.9738.2 (87.0) 104.7738.4 (102.2)
PRISM IIa 12.477.2 (13.0) 15.478.6 (16.0)
Baseline eCCl
(ml/min/1.73 m2)b
132746 (119) 1597100 (129)
Peak mean airway
pressure (mm Hg)
15.078.2 (12.0) 17.279.2 (14.0)
Days ventilated 10.7711.3 (8.0) 15.8718.7 (9.0)
PICU length of stay 10.176.2 (9.0) 18.0724.3 (11.0)*
Hospital length of
stay
20.5716.6 (14.0) 36.6740.1 (22.0)**
Categorical variables, N (%)
Ethnicity
Caucasian 11 (40.7) 41 (33.3)
African-American 5 (18.5) 25 (20.3)
Hispanic 8 (29.6) 55 (44.7)
Asian 3 (11.1) 2 (1.6)
Male 11 (40.7) 56 (45.5)
Comorbidities
Present 17 (63) 89 (72.4)
Hematology/oncology 1 (3.7) 15 (12.2)
Cardiology 2 (7.4) 20 (16.3)
Otherb 14 (52) 55 (44.7)
Admitting diagnosis
Pneumonia 11 (41) 40 (33)
SIRSc/sepsis/septic
shock
5 (18.5) 33 (26.8)
Cardiac arrest 6 (22) 12 (10)
Other 5 (18.5) 38 (30.9)
Clinical
Need for pressors 13 (48.2) 66 (53.7)
Need for RRTd 0 11 (8.9)
28-Day mortality 3 (11.1) 18 (14.6)
AKI, acute kidney injury; eCCl, estimated creatinine clearance; PICU, pediatric
intensive care unit; RIFLE, risk, injury, failure, loss and end-stage renal disease.
*Po0.07; **Po0.05.
aPRISM, Pediatric Risk of Mortality II score.
bOther includes the following diagnostic categories: endocrine, failure to thrive,
gastrointestinal, rheumatologic, neurological (cerebral palsy, and epilepsy), ortho-
pedic, pulmonary, psychiatric.
cSIRS, systemic inflammatory response syndrome.
dRRT, Renal replacement therapy.
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severity distribution did not differ between patients with vs
without NMd.
Eleven patients received RRT. Continuous venovenous
hemodialysis was provided for 10 patients; one patient
initiated hemodialysis but was converted to continuous
venovenous hemodialysis after two treatments. Nine of these
patients had pRIFLE F AKI and two had pRIFLE I at RRT
initiation. The decision to initiate RRT was made on the basis
of clinical and laboratory grounds by the attending
nephrologist and not by using pRIFLE criteria. Two patients
with pRIFLE I AKI were stem cell transplant recipients who
required RRT for fluid overload prevention per our
institution’s protocol,16 and the remaining nine patients
were dialyzed primarily for uremia. These nine patients were
older than the remaining 22 patients with pRIFLE F AKI who
did not receive RRT (10.475.5 vs 6.576.6 years, Po0.05),
but did not differ significantly in gender distribution, PRISM
II score, nor proportion diagnosed with sepsis (not shown).
Although mortality was similar in the groups (29% for
pRIFLE F and no RRT vs 22% in those who received RRT,
P40.05), PICU LOS and hospital LOS were longer in those
who received dialysis (PICU LOS: 12.678.5 (median¼ 10) vs
25.3713.1 days (median¼ 22), respectively; hospital LOS:
40.7759.0 (median¼ 22) vs 60.6740.0 days (median¼ 46)
respectively, both Po0.05). This may have been explained by
the fact that 71% (5/7) of non-surviving patients with
pRIFLE F AKI who did not receive RRT died within 24 h of
pRIFLEmax F attainment.
Distribution of pRIFLE by SCr vs UOP criteria
Ninety-seven patients (81.5%) fulfilled pRIFLECr criteria and
65 (54.6%) fulfilled pRIFLEUOP criteria at some time during
the study period. Of the 11 patients who received dialysis,
four had not attained pRIFLEUOP status before initiating
dialysis. These four patients were included in the group who
only attained pRIFLECr for this analysis. All patients
requiring dialysis attained their pRIFLECrmax before initia-
tion of dialysis.
Table 2 lists outcome based on the type of RIFLE criteria
achieved. Forty-three patients (35.0%) attained both pRI-
FLECr and pRIFLEUOP AKI (pRIFLECrþUOP), 58 (47.2%)
only pRIFLECr criteria and 22 (17.9%) attained only
pRIFLEUOP (Table 2). Patients with pRIFLECr only tended
to be younger (Table 2). Patients with pRIFLEUOP only had
lower PRISM II scores (Po0.05, analysis of variance), and
none of them died or required dialysis. Mortality was
higher for patients with pRIFLECr (SCr only or SCrþ urine
output) compared with the group that only attained
pRIFLEUOP criteria (both Po0.05). Mortality in the
pRIFLECrþUOP group did not differ compared with the
pRIFLECr only group.
Table 3 displays pRIFLECrmax and pRIFLEUOPmax for the
43 patients who attained pRIFLE AKI criteria by both SCr
and UOP categories. Only six patients attained a pRIFLEUOP-
max that was worse than their pRIFLECrmax; none of whom
received dialysis or died. Only four patients attained any
pRIFLEUOP before attaining any pRIFLECr; none of these
patients later received dialysis.
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Figure 1 | Distribution of the day of admission that subjects
reached pRIFLEmax (n¼ 123) and pRIFLE F stratum (n¼ 31).
Black bars indicate numbers of subjects attaining their pRIFLEmax AKI
on a given day, and gray bars indicate numbers of subjects attaining
their first pRIFLE F on a given day. The majority of subjects (82%)
reached their maximum pRIFLE stratum for AKI (black) within the first
week of admission, and most patients who reached pRIFLE F AKI did
so within the first week of admission (25/31¼ 81%, gray bars).
All 150 patients
N=124
No NMd
N=26
NMd
AKI No AKI AKI No AKI
N=21 (80.8%) N=5 (19.2%) N=102 (82.3%) N=22 (17.7%)
maxR maxI or F maxR maxI or F
9/21 (42.9%) 12/21 (57.1%) 51/102 (50%) 51/102 (50%)
1/9 (11.1%) 6/12 (50%) death 2/5 (40%) death 4/51 (7.8%)  7/51 (13.7%) death 1/22 (4.6%)
    death
 death 0 RRT 1/12 (8.3%)RRT 0 RRT  death 0 RRT 10/51 (19.6%) RRT
Figure 2 | Flow diagram indicating the distribution of AKI and outcome (survival and need for RRT), comparing patients with and
without chronic a neuromuscular disease (NMd, neuromuscular disease; maxR/maxI/maxF, maxiumum pRIFLE stratum attained
during admission; RRT, renal replacement therapy).
1030 Kidney International (2007) 71, 1028–1035
o r i g i n a l a r t i c l e A Akcan-Arikan et al.: AKI in critically ill children
AKI on admission: early reversal vs persistent AKI
We examined separately a subgroup of patients with AKI at
the time of admission to the PICU (Figure 3). Fifty-two
(42.3%) patients had AKI on the day of admission: 16
(30.8%) had pRIFLE R, 21 (40.4%) had pRIFLE I, and 15
(28.8%) had pRIFLE F. Patients with AKI on admission had
higher PRISM II scores than patients who developed AKI
after day 1 (18.978.9 vs 12.877.4, P¼ 0.0001). A higher
proportion of patients with AKI on admission received RRT
than patients who developed AKI after day 1 (10/52 vs 1/71
(P¼ 0.001)); the association between AKI on admission and
the need for dialysis was independent of age and gender
(logistic regression, P¼ 0.004).
Renal function substantially improved (as defined by a
decrease in pRIFLE stratum) within 48 h (‘early reversal’) in
46% of patients with AKI at PICU admission. Early reversal
of AKI was more likely to occur in patients with pRIFLE R on
admission (10/16, 62.5%), than in those with pRIFLE I (8/21,
38.1%) or F (4/15, 26.7%) on admission. Fewer patients in
the early reversal group received RRT than in the group with
persistent AKI (1/22 (4.5%) vs 10/30 (33.3%), respectively,
Po0.03); this association was also independent of age and
gender (logistic regression, P¼ 0.0001).
Outcomes
AKI and LOS (PICU and hospital). In univariate analyses,
patients with AKI tended to have a longer PICU LOS when
compared with control patients (18.0724.3 vs 10.176.2
days, P¼ 0.06). Hospital LOS was significantly longer for
patients with AKI compared with the control group
(36.6740.1 vs 20.5716.6 days, P¼ 0.04). Table 4 lists Cox
regression analysis for PICU and hospital LOS adjusting for
age and gender and accounting for death as a censoring
event. The presence of any AKI, of pRIFLEmax I or F, and of
pRIFLEmax F during the study period were each indepen-
dently associated with longer hospital LOS. The presence of
AKI during the study period was independently associated
with longer PICU LOS. The presence of AKI pRIFLE I or F on
admission was associated with longer hospital LOS. Patients
with persistent admission AKI (no improvement within 48 h)
did not demonstrate longer hospital or PICU LOS, compared
with all other patients.
Mortality
Figures 2 and 3 display the distribution of survival outcome,
examining the whole sample (Figure 2) and those with AKI
on admission (Figure 3). Overall mortality rates did not
differ between patients with AKI (14.6%) vs those without
AKI (11.1%). However, patients with pRIFLEmax I or F
during admission had over twice the mortality than patients
with pRIFLEmax R or controls (21 vs 8%, respectively,
Po0.05). Patients with pRIFLEmax F also had over twice the
mortality rate of the rest of the cohort (25.8% for
pRIFLEmax F vs 10.9% for all others, P¼ 0.03).
Patients with chronic NMd had a higher mortality rate
than the rest of the cohort (35 vs 10%, Po0.05; Figure 2).
Because AKI rates were not different in the NMd group, NMd
was not a confounder of the effect of AKI on mortality. Using
logistic regression, controlling for age, gender, PRISM II
Table 3 | Two-by-two table depicting the maximum pRIFLECr
and maximum pRIFLEUOP attained during the study period, in
patients who attained pRIFLE AKI by SCr and urine output
criteria
Urine pRIFLEmax
R I F Total
SCr pRIFLEmax
R 13 5 1 19
I 5 3 0 8
F 3 3 10 16
Total 21 10 9 43
AKI, acute kidney injury; pRIFLE, pediatric risk, injury, failure, loss and end-stage renal
disease; SCr, serum creatinine.
Dark gray: six patients had higher pRIFLEUOPmax than pRIFLECrmax.
Light gray: 26 patients had the same pRIFLEUOPmax as their pRIFLECrmax.
Table 2 | Comparison of characteristics and outcomes of
patients with AKI, based on their attainment of pRIFLE
criteria by urine output only (pRIFLEUOP), by SCr only
(pRIFLECr), or by both (pRIFLECr+UOP)
pRIFLEUOP
only N=22
pRIFLECr only
a
N=58
pRIFLESCr+UOP
N=43
Age
Mean7s.d.
(median)
8.575.9 (7.5) 4.375.8 (1.0)b 8.676.4 (8.0)
PRISM
Mean7s.d.
(median)
10.677.8 (8.0)c 15.877.9 (15.5) 17.479.1 (18.0)
Males
N/total (%) 12/22 (54.6) 28/58 (48.3) 27/43 (62.8)
28-Day mortality
N/total (%) 0 9/58 (15.5)d 9/43 (20.9)d
Need for dialysis
N/total (%) 0 5/58 (8.6) 6/43 (14.0)e
pRIFLEmax
pRIFLEmax R
N/total (%) 18/22 (81.8) 29/58 (50.0) 13/43 (30.2)
pRIFLEmax I
N/total (%) 3/22 (13.6) 16/58 (27.6) 13/43 (30.2)
pRIFLEmax F
N/total (%) 1/22 (4.5) 13/58 (22.4) 17/43 (39.5)
ANOVA, analysis of variance; AKI, acute kidney injury; KI, kidney injury; pRIFLE,
pediatric risk, injury, failure, loss and end-stage renal disease; PRISM, Pediatric Risk of
Mortality score; SCr, serum creatinine.
aPatients who attained pRIFLE urine output criteria only after dialysis was initiated
were included in the SCr pRIFLE only group.
bAKI patients who only attained pRIFLE criteria by SCr were statistically significantly
younger than patients in the other groups (Po0.05, ANOVA).
cKI patients who only attained pRIFLE criteria by urine output had statistically
significantly lower PRISM scores than the other two groups.
d28-day mortality was higher in both AKI groups with SCr pRIFLE criteria attainment
(Po0.05) compared with the group with only urine output pRIFLE criteria.
eThe need for dialysis tended to be higher in both groups that attained SCr pRIFLE
criteria compared with the group that only attained urine output pRIFLE criteria, but
the difference did not achieve statistical significance (Po0.1).
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score, the association between AKI during admission and
mortality was no longer significant (Table 5). However, when
AKI was defined only by SCr criterion, pRIFLECrmax I or F
was independently associated with an increased risk of
mortality (Table 5). When PRISM II score was removed from
all regression models, the effects of the different expressions
of AKI on mortality appeared more important, with most
odds ratios increasing substantially (Table 5).
The presence of AKI on admission was not an indepen-
dent risk factor for mortality. Patients with AKI on admission
who did not improve in pRIFLE stratum within 48 h
(persistent AKI, n¼ 30) did not have a higher risk of
mortality compared with the rest of the cohort, when
controlled for age, gender, and PRISM II score (Table 5).
DISCUSSION
The current prospective study shows pRIFLE to serve well to
both classify pediatric AKI epidemiology and reflect the
course of AKI in children admitted to the PICU. AKI
classification using pRIFLE criteria revealed that AKI is very
common in critically ill pediatric patients and is associated
with significant morbidity.
AKI occurred very early in the PICU course, most often
within the first week of admission, and patients who did not
develop AKI within the first 7 days of PICU admission were
very unlikely to develop AKI later. These data support
previous pediatric studies demonstrating that children
develop their maximum number of organ failures early in
the intensive care unit (ICU) course, an epidemiologic
pattern that differs from adult patients.17,18 In addition,
patients who did not demonstrate renal function improve-
ment within 48 h of ICU admission were at greater risk of
receiving RRT, which is similar to studies in adult patients.19
These data suggest the need to study the effect of early
initiation of aggressive measures to both prevent and treat
AKI for critically ill children with AKI who do not improve
52 patients with AKI on admission
Admission
pRIFLE stratum 16 (30.8%) R 36 (69.2%) I or F
48 h after
admission 10/16 (62.5%) 6/16 (37.5%) 12/36 (33.3%) 24/36 (66.7%)
No PersAKI PersAKI No PersAKI PersAKI
Final 1/10 (10%) died 1/6 (16.7%) died 0 died 6/24 (25%) died 
outcome 0 RRT 1/6 (16.7%) RRT and died 1/12 (8.3%) RRT 7/24 (29.2%) RRT2/16 (12.5%) total deaths 2/24 (8.3%) RRT and died
8/24 (33.3%) total deaths
No difference in % PersAKI had higher % deaths*
 deaths or % RRT. No difference in % RRT (p=0.06)
Figure 3 | Flow diagram of the course of AKI, for patients with AKI on the day of admission (n¼ 52). Most deaths occurred in
patients with pRIFLE I or F on admission who had persistent AKI, defined as lack of improvement in AKI pRIFLE stratum within 48 h.
Table 4 | The effect of different criteria for AKI on hospital
and PICU length of stays, independent of age and gendera
Hospital LOS-
adjusted HR
(95% CI)b
PICU LOS-
adjusted HR
(95% CI)b
AKI during the PICU stay
Using SCr+urine output criteria
Any AKI during admxc 0.6 (0.4–0.9)* 0.6 (0.4–0.9)*
pRIFLEmax I or F 0.6 (0.4–0.9)* 0.7 (0.5–0.9)*
pRIFLEmax F 0.6 (0.4–0.9)* 0.8 (0.5–1.2)
Using SCr criterion only
Any AKI during admxc 0.5 (0.3–0.7)* 0.4 (0.3–0.6)*
pRIFLEmax I or F 0.5 (0.4–0.8)* 0.6 (0.4–0.8)*
pRIFLEmax F 0.6 (0.4–0.9)* 0.7 (0.5–1.1)
AKI on admission to PICU
Using SCr+urine output criteria
AKI on admx 0.7 (0.5–1.01) 0.9 (0.6–1.2)
AKI pRIFLE I or F on admx 0.6 (0.4–0.9)* 0.7 (0.5–1.03)
AKI on admx with persistent
AKId
0.8 (0.5–1.1) 0.8 (0.6–1.3)
AKI pRIFLE I or F on admx
with persistent AKI
0.7 (0.4–1.1) 0.8 (0.5–1.2)
Using SCr criterion only
AKI on admx 0.7 (0.5–0.96) 0.8 (0.6–1.2)
AKI pRIFLE I or F on admx 0.6 (0.4–0.9)* 0.7 (0.5–1.03)**
AKI on admx with persistent
AKId
0.8 (0.5–1.1) 0.8 (0.6–1.3)
AKI pRIFLE I or F on admx
with persistent AKI
0.7 (0.4–1.1) 0.8 (0.5–1.2)
AKI, acute kidney injury; CI, confidence intervals; HR, hazard ratio; LOS, length of
stays; PICU, pediatric intensive care unit; pRIFLE, pediatric risk, injury, failure, loss and
end-stage renal disease; SCr, serum creatinine.
*Hazard ratio is significantly less than 1.0, indicating that the specified AKI criterion
was associated with a longer length of stay (longer time to discharge).
**P=0.07.
aAll analyses were also conducted including PRISM score, which is a risk of mortality
score, but there was no effect of this factor on results shown.
bAll Cox proportional hazards models fulfilled assumption of proportional hazard
based on Schoenfeld residuals.
cAdmx, admission.
dPersistent AKI was defined as a lack of improvement in pRIFLE AKI status by 48 h
after admission.
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within 24–48 h. Numerous single center and one multicenter
study of children requiring continuous renal replacement
therapy have shown a strong association between the degree
of fluid overload at continuous renal replacement therapy
initiation and mortality.7–10,16 We suggest that the pRIFLE
criteria may be used to provide guidance as to the potential
for renal function improvement and may assist in clinical
decisions regarding RRT initiation. The high prevalence of
AKI on admission to PICU in our sample suggests that study
of risk factors (clinical and biochemical) for developing AKI,
may need to include data from patients before ICU
admission.
Other secondary outcomes were notable as well. The
presence of RIFLE I or F AKI (defined by SCr criterion only)
during admission was associated with an increased risk of
mortality, even when adjusted for PRISM II score. This
finding is important since PRISM II does not contain a direct
measure of renal function in its calculation. Surprisingly, the
prevalence of comorbidities, sepsis or other admission
diagnoses were no different for patients with vs without
AKI, even though AKI was associated with mortality,
suggesting that AKI is an independent risk factor for death.
Although this observation is consistent with similar results
from recent study of RIFLE criteria in critically ill adult
patients,20,21 it should be interpreted with caution because
our sample size may not have been large enough to detect
differences between subgroups. Future study should evaluate
the interaction of diagnosis and AKI on mortality risk. When
PRISM II scores were excluded from analysis, the effect of
AKI on mortality appeared substantially stronger, stressing
the importance of controlling for severity of illness when
assessing for associations between AKI and mortality.
Approximately 71% of patients who attained pRIFLE F
AKI did not receive RRT, which might suggest that the
pRIFLE criteria is overly sensitive for identifying severe AKI.
However, over two-thirds of these patients died within 24 h
of pRIFLEmax F attainment. Had these patients survived, it is
possible that they would have required RRT. Although these
findings are purely descriptive, they do further indicate that
patients with severe AKI tend to be more severely ill, and that
future studies evaluating risk factors for initiation of RRT
may need to account for censoring owing to death.
Our evaluation for potential differences in outcome as a
function of attaining AKI by serum SCr vs UOP vs both
revealed that SCr demonstrated stronger associations with
outcomes. Future studies may be needed to determine if UOP
is in fact necessary for early AKI diagnosis; however, we still
suggest assessment of both the SCr and UOP measures for
AKI.
Potential limitations of our study include the relatively
small sample size of 150; however, this cohort comprises the
largest prospective evaluation of pediatric AKI and the only
study describing AKI in a general PICU population (as
opposed to specific subgroups). Another potential concern is
the use of an assumed baseline eCCl of 100 ml/min/1.73 m2
for patients without a known baseline creatinine, in about
one-fourth of the patients. The potential danger of this
assumption would be to misdiagnose a patient with AKI
based on a relative decrease in eCCl if in fact the patient had
chronic kidney disease. Whether or not such misdiagnosis
would lead to unnecessary evaluation or treatment is
currently not known, but clinicians should exercise caution
when classifying patients with AKI using pRIFLE, or any
system using eCCl change, when a baseline creatinine level is
unknown. Finally, the decision to initiate RRT was not
directed by a clinical algorithm as part of this study, but
rather was left to the discretion of the attending nephrologist.
Thus, RRT provision was not a hard end point for this study.
Because of the dependency of SCr levels on muscle mass, it
is extremely difficult to interpret in patients with severely
reduced muscle mass (such as those with quadriplegia,
cerebral palsy or other neuromuscular disorders), as is
Table 5 | Association of different criteria for AKI and mortality
and the effect of controlling for severity of illness (PRISM II
score)
28-Day mortality
Adjusted OR
(95% CI)a
Adjusted OR
(95% CI)a (no
PRISM II score)
AKI during the PICU stay
Using SCr + urine criteria
Any AKI during admxb 1.1 (0.3–4.3) 1.4 (0.4–5.1)
pRIFLEmax I or worse 1.9 (.7–5.1) 1.7 (0.6–4.8)
Using only SCr criterion
Any AKI during admxb 2.9 (0.8–10.9) 3.6 (1.0–13.1)
pRIFLEmax I or worse 3.0 (1.1–8.1)* 3.8 (1.4–10.0)*
AKI on admission to PICU
Using SCr + urine criteria
AKI on admx 1.2 (0.4–3.4) 1.8 (0.7–4.6)
AKI pRIFLE I or worse
on admx
1.1 (0.4–3.4) 1.7 (0.6–4.8)
AKI on admx with
persistent AKIc
2.6 (0.9–7.9) 3.9 (1.4–10.6)*,d
AKI pRIFLE I or worse on
admx with persistent AKI
2.3 (0.8–7.2) 3.4 (1.2–9.8)*,d
Using only SCr criterion
AKI on admx 1.7 (0.6–5.0) 2.5 (1.0–6.5)
AKI pRIFLE I or worse on
admx
1.3 (0.5–4.0) 2.0 (0.7–5.4)
AKI on admx with persistent
AKIc
2.6 (0.9–7.9) 3.9 (1.4–10.6)*,d
AKI pRIFLE I or worse on
admx with persistent AKI
2.3 (0.8–7.2) 3.4 (1.2–9.8)*,d
AKI, acute kidney injury; CI, confidence intervals; LOS, length of stays; OR, odds ratio;
PICU, pediatric intensive care unit; PRISM, Pediatric Risk of Mortality score; pRIFLE,
pediatric risk, injury, failure, loss and end-stage renal disease; SCr, serum creatinine.
*Po0.05.
aIn the first column, all odds ratios are adjusted for age, gender, and Pediatric Risk of
Mortality score; in the second column, odds ratios are only adjusted for age and
gender.
bAdmx, admission.
cPersistent AKI was defined as no improvement in pRIFLE AKI status by 48 h after
admission.
dWhen PRISM II score was removed from the logistic regression model, AKI on
admission with persistent AKI was a significant predictor of mortality (only adjusted
for age and gender).
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evidenced by our data where patients in the NMd category
had mean eCCl of 232 ml/min/1.73 m2. We thus questioned
whether the pRIFLE criteria would be less useful in this
group. The finding that the distribution of AKI severity was
almost identical in the NMd group (Figure 2) is highly
suggestive that change in eCCl, as assessed by pRIFLE, is a
valid way of evaluating AKI in patients with severely reduced
muscle mass. What is not known is whether progressive
muscle – wasting associated with prolonged ICU admis-
sion,22,23 which may be associated with declining levels of
SCr independent of renal function, leads to a decrease in the
utility of pRIFLE for describing AKI.
We conclude that multidimensional AKI classification and
stratification systems, such as pRIFLE, can serve well to
improve understanding of AKI epidemiology and potentially
optimize evaluation and treatment for AKI in children.
Furthermore, as SCr and UOP seem to be late markers of
renal injury, use of classification systems will be essential to
assess the potential utility of urine and other serum
biomarkers to detect AKI earlier and direct therapies to
prevent or mitigate AKI in children prior to a rise in SCr
concentration.
MATERIALS AND METHODS
We prospectively studied patients admitted to the Texas Children’s
Hospital PICU using pediatric-modified RIFLE (pRIFLE) criteria
(Table 6) to define the clinical course of AKI in the critically ill
pediatric patients. All children aged between 30 days to 21 years with
respiratory failure (defined as requiring invasive mechanical
ventilation) and/or cardiovascular failure (defined as requiring
infusion of vasoactive medication(s)) who had indwelling Foley
catheters were eligible for enrollment. Patients with known end-
stage renal disease at PICU admission or who were immediately
status-post renal transplant were excluded. The Institutional Review
Board of Baylor College of Medicine approved the study protocol
and parents/legal guardians provided written informed consent
before patient enrollment.
UOP and SCr concentrations were recorded daily for up to 14
days and eCCl was calculated using the Schwartz formula.24 For
determination of baseline eCCl, the lowest value of SCr in the 3
months preceding study enrollment was obtained from the hospital
database. If no previous SCr was available, the patient was assumed
to have normal renal function and assigned a baseline eCCl of
100 ml/min/1.73 m2, as suggested. Data were reviewed daily and
patients were assigned to the appropriate pRIFLE strata (R, I or, F) if
they fulfilled either UOP (pRIFLEUOP) or SCr (pRIFLECr) criterion
or both (Table 1). At the end of follow-up, patients were classified
according to the maximum pRIFLE stratum achieved within the 14
days of observation (pRIFLEmax). Additional data collected
included demographics, PICU admission and discharge diagnoses,
the presence of chronic illnesses, duration of invasive mechanical
ventilation, peak mean airway pressure reached, maximal number of
vasoactive medication infusions, and the need for dialysis. PRISM II
scores25 were recorded for each patient on PICU admission, as a
surrogate marker for severity of illness. Hospital and PICU LOS, and
28 day and hospital mortality were recorded.
Comparison of pre-renal azotemia vs acute tubular necrosis
Intravascular fluid depletion is a common cause of increased SCr/
decreased glomerular filtration rate in the pediatric setting
(commonly referred to as ‘pre-renal azotemia’), particularly early
in the PICU admission. Such patients will often respond solely to
fluid repletion, with a return of SCr to baseline values within
24–48 h of fluid resuscitation. On the basis of this rationale, we
chose to compare the renal outcome and mortality of patients with
early AKI reversal (improving pRIFLE stratum within 48 h of ICU
admission) vs patients with persistent AKI (no improvement in
pRIFLE stratum by 48 h), to serve as a surrogate for pre-renal
azotemia vs acute tubular necrosis.
Statistical analysis
All statistical analyses were performed using STATAs (StataCorp,
College Station, TX, USA) software. Continuous variables were
expressed as mean7s.d. and median, and categorical variables as
proportions (%). Continuous variables were compared using
analysis of variance and Student’s t-test. w2 and Fisher’s exact tests
were used for comparison of categorical variables. The outcomes
examined were mortality, and PICU and hospital LOS. Multiple
logistic regression was used to evaluate the presence of AKI and
other relevant variables as risk factors for mortality. Cox-multiple
regression was performed to evaluate the effect of AKI on time to
PICU and hospital discharge, accounting for death as a censoring
event. Continuous variables with a non-normal distribution were
log-transformed to a normal distribution for use in parametric
analyses. In all analyses, a P-value of o0.05 was considered
statistically significant.
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